FindTrial
Sign In

A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants

A multicentre, observational, prospective study of the current practice in major centres in Australia and New Zealand for achieving haemostasis in consecutive patients who present with significant haemorrhage, thromboembolism or urgent surgery whilst on new or established oral anticoagulants

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12613001304729
Acronym
ARES Collaborative
Enrollment
2000
Registered
2013-11-22
Start date
2012-05-20
Completion date
2015-09-30
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

To document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage or require anticoagulant reversal for urgent surgery and/or a procedure whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. In patients whilst on oral anticoagulants who present with embolism, determine the circumstances and level of anticoagulation at the time of presentation.

Interventions

This is an observational study to document in major centres in Australia and New Zealand the current practice for achieving haemostasis in patients who present with significant haemorrhage, thromboembolism or require anticoagulant reversal for urgent surgery and/or a procedure whilst on new (dabigatran, rivaroxaban, or apixaban) or established (warfarin) oral anticoagulants. The duration of the study is 42 months.

Sponsors

ARES Collaborative
Lead SponsorOther Collaborative groups

Eligibility

Sex/Gender
All
Age
0 to No maximum
Healthy volunteers
No

Inclusion criteria

Patients presenting with significant haemorrhage, thromboembolism or require anticoagulation reversal for urgent surgery and/or a procedure and have taken a NOAC (dabigatran, rivaroxaban, or apixaban) or warfarin within the last 7 days.

Exclusion criteria

Patients who have minor haemorrhage responding to local measures not requiring admission, blood testing or change in anticoagulant management. Patients who are unable to have objective testing for recurrence of thromboembolism.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026